Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy

European Heart Journal

Volumn 19, Issue 4, 1998, Pages 623-627

  Capaldo, B ^a   Lembo, G ^b   Rendina, V ^a   Vigorito, C ^a   Guida, R ^a   Cuocolo, A ^a   Fazio, S ^a   Sacca L ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS NEUROMED   (Italy)

^c Medicina Interna   (Italy)

Author keywords

Cardiomyopathy; Growth hormone; Sympathetic nervous system

Indexed keywords

ALDOSTERONE; GROWTH HORMONE; HUMAN GROWTH HORMONE; NORADRENALIN; POTASSIUM ION; SODIUM ION;

ADRENERGIC SYSTEM; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BLOOD FLOW; CORONARY VEIN; DISEASE COURSE; EXERCISE; FEMALE; HEART FAILURE; HEART MUSCLE; HUMAN; MALE; NORADRENALIN RELEASE; PLASMA VOLUME; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REST; SODIUM BLOOD LEVEL; STANDING; SUBCUTANEOUS DRUG ADMINISTRATION; SUPINE POSITION; SYMPATHETIC TONE;

ADULT; CARDIOMYOPATHIES; EXERCISE; FEMALE; HEART CATHETERIZATION; HEMODYNAMIC PROCESSES; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIUM; NOREPINEPHRINE; SYMPATHETIC NERVOUS SYSTEM;

EID: 0031978234     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0805     Document Type: Article

References (24)

1. Saccà L, Fazio S. Cardiac performance: growth hormone enters the race. Nature Med 1996; 2: 29-31.
2. Ambler GR, Johnston BM, Maxwell L, Gavin JB, Gluckman PD. Improvement of doxorubicin-induced cardiomyopathy in rats treated with insulin-like growth factor I. J Cardiovasc Res 1993; 27: 1368-73.
3. Duerr RL, Huang S, Miraliakbar HR, Chien K, Ross Jr. J. Insulin-like growth factor 1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-27.
4. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-7.
5. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 1995; 26: 420-5.
6. Fazio S, Sabatini D, Capaldo B et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14.
7. Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sønksen PH. Cardiac failure responding to growth hormone. Lancet 1989; 1: 838-9.
8. Frustaci A, Perrone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992; 97: 503-11.
9. Fazio S, Biondi B, Sabatini D et al. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. J Clin Endocrinol Metab 1996; 81: 887-90.
10. Packer M, Lee WH, Kessler PD, Gottlied SS, Bernstein JL, Kukin M. Role of neurohormonal mechanisms in determining the survival of patients with severe chronic heart failure. Circulation 1987; 75 (Suppl IV): 80-92.
11. Packer M. Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms. Am J Cardiol 1992; 69: 150G-4G.
12. Trimarco B, Lembo G, De Luca N et al. Blunted sympathetic response to cardiopulmonary receptor unloading in hypertensive patients with left ventricular hypertrophy. A possible compensatory role of atrial natriuretic factor. Circulation 1989; 80: 883-92.
13. Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism Clin Exp 1990; 39: 133-7.
14. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-73.
15. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26: 1257-63.
16. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
17. Xiang J, Linz W, Becker H et al. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated rate heart. Eur J Pharmacol 1984; 113: 215-23.
18. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990; 70: 963-85.
19. Port JD, Gilbert JM, Larrabee P et al. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation 1990; 81: 929-38.
20. Eisenhofer G, Friberg P, Rundqvist B et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1667-76.
21. Weber K, Brilla C, Janicki J. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341-8.
22. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol 1993; 71: 34A-39A.
23. Tait JF, Bougas J, Little B, Tait SAS , Fllod C. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol 1965; 25: 219-28.
24. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-5.